Lenalidomide Maintenance Therapy for Plasma Cell Myeloma

Inclusion Criteria

• Adults aged 18 and older who have been treated for plasma cell myeloma and show stable disease or better.
• Must have good overall health, with specific blood counts and organ functions within acceptable ranges.
• Must be registered in the Revlimid REMS® program and agree to follow its requirements.
• Women of childbearing potential must have a negative pregnancy test and agree to use two forms of birth control.
• Men must agree to use a condom during sexual activity with women who can become pregnant.
• Must be able to take daily blood-thinning medication like aspirin.
• Must understand and agree to sign a consent form to participate.

Exclusion Criteria

• Patients whose myeloma is worsening or not responding to treatment.
• Patients who have not responded to lenalidomide in their most recent treatment.
• Patients taking other experimental treatments for myeloma.
• Women who are pregnant or breastfeeding.
• Patients with uncontrolled high blood pressure or diabetes.
• Patients with active hepatitis B or C infections.
• Patients with another cancer diagnosis within the last 3 years, except for certain skin cancers.
• Patients with HIV or those on treatment for HIV/AIDS.
• Patients who have had an organ transplant or stem cell transplant.
• Patients with recent heart problems or severe heart conditions.
• Patients with conditions that prevent them from absorbing the study drug.
• Patients with severe nerve damage or who cannot take blood-thinning medication.
• Patients who have had major surgery within the last month.
• Patients who have had severe reactions to thalidomide or lenalidomide in the past.